Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1636097

Cc1c2nc3ccc(NC(=O)CCN)cc3oc-2c(C)c(=O)c1C.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
POLB P06746 1/20 0.40
ALDH1A1 P00352 5/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
TERT O14746 2/20 0.38
KDM4E B2RXH2 5/20 0.37
GAA P10253 4/20 0.37
HPGD P15428 4/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TP53 P04637 2/20 0.36
THRB P10828 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719827 0.93 POLB (0.45) SMN1; SMN2POLBALDH1A1ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL1636823 0.85 SMN1; SMN2 (0.45) SMN1; SMN2POLBALDH1A1ITGB3ITGA2B
SCHEMBL1635346 0.78 KDM4E (0.41) SMN1; SMN2POLBALDH1A1KDM4EGAA
SCHEMBL1719631 0.77 TERT (0.43) SMN1; SMN2POLBALDH1A1ITGB3ITGA2B
SCHEMBL16069594 0.71 ALDH1A1 (0.41) SMN1; SMN2POLBALDH1A1KDM4EKMT2A
SCHEMBL18924201 0.69 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDMAPTMEN1
SCHEMBL16069568 0.69 KDM4E (0.47) SMN1; SMN2ALDH1A1KDM4EHPGDMAPT
SCHEMBL5483503 0.69 ADORA3 (0.41) POLBALDH1A1KDM4EGAAHPGD
SCHEMBL16062313 0.68 MAPT (0.49) SMN1; SMN2POLBALDH1A1KDM4EHPGD
SCHEMBL16069632 0.66 MAPT (0.52) SMN1; SMN2POLBALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932050-B2 Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2011-04-26 US disclosed
US-20100028926-A1 Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity BIOMERIEUX (FR) 2010-02-04 US disclosed
US-7626018-B2 Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity bioMérieux (FR) 2009-12-01 US disclosed
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity BIOMERIEUX (FR) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293094-A1 Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity PEPD, CTRL, PREP SMN1; SMN2 4717/4885POLB 1528/4885ALDH1A1 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.